Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 12/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474256 | 0.77 | SMN1; SMN2 (0.48) | CTSAHPGDS | |
| SCHEMBL1803210 | 0.77 | DPP4 (0.38) | CTSAHPGDSLTA4HSLC6A2SLC6A4 | |
| SCHEMBL4004965 | 0.77 | TSHR (0.38) | CTSAHPGDSLTA4HSLC6A2SLC6A4 | |
| SCHEMBL20773298 | 0.74 | TAAR1 (0.52) | CTSACNR1 | |
| SCHEMBL4884994 | 0.74 | TSHR (0.50) | CTSASLC6A2SLC6A4CNR1 | |
| SCHEMBL6426003 | 0.73 | CYP2D6 (0.44) | CTSA | |
| Hydrochloric Acid SCHEMBL9634886 | 0.72 | KDM4E (0.37) | CTSAHPGDSLTA4HSLC6A2SLC6A4 | |
| SCHEMBL4805668 | 0.70 | CTSA (0.42) | CTSA | |
| SCHEMBL20773664 | 0.70 | TAAR1 (0.43) | CTSASLC6A2SLC6A4SLC6A3CNR1 | |
| SCHEMBL27913105 | 0.69 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| EP-3676266-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | Ctxt Pty Ltd (AU) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | KAT5, KAT6A, KAT2A | CTSA 3581/4885HPGDS 2694/4885LTA4H 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.